AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02640846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Levosimendan will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
Study NCT02509598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m tilmanocept
Description: A single dose of 0.5 mCi and 50 ug of Tc99m tilmanocept administered intradermally, peritumorally approximately 15 minutes to 8 hours before surgery
Study NCT02509598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vital Blue Dye (optional)
Description: A single dose 1-3 mL of vital blue dye (1%) administered intradermally at the start of or during surgery (optional, per institution's standard of care).
Study NCT02509598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Mapping
Description: Intraoperative lymph node mapping will occur 15 minutes to 8 hours after Tc99m tilmanocept injection
Study NCT03623139 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard nutritional education
Description: Routine dietary care consists of three individual consultations with a trained dietitian. The individual guidance will be in accordance with the dietary guidelines in type 2 diabetes.
Study NCT03623139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic carbohydrate counting
Description: The BCC concept is a group-based program consisting of three group sessions delivered by trained dietitians.
Study NCT02147704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High-sodium diet
Description: 1. One of high- or low sodium intake for 7 days during each period~2. High sodium intake: 50 mmol/day by diet + 250 mmol/day by salt tablets
Study NCT02147704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: low-sodium diet
Description: 1. One of high- or low sodium intake for 7 days during each period~2. Low sodium intake : 50 mmol/day by diet
Study NCT04153006 — intervention group
Intervention type: DEVICE
Intervention: POC troponin analysis.
Description: Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Minicare® device.
Study NCT03209180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CarVeDilol-SR (Slow Release)
Description: patients will receive slow-release carvedilol (SR) once daily
Study NCT03209180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol IR (Immediate Release)
Description: patients will receive immediate release carvedilol (IR) twice daily
Study NCT03051334 — intervention group
Intervention type: OTHER
Intervention: diagnosed as bicuspid aortic valve
Study NCT05219422 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project ALERT
Description: 14 session drug prevention program for 7th and 8th grade youth.
Study NCT05219422 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Getting to Outcomes
Description: The Getting To Outcomes (GTO) implementation support intervention provides technical assistance, training, guides, and tools to improve community-based practitioners capacity to complete tasks associated with implementing an EBP, which in turn leads to improved implementation fidelity.
Study NCT02406547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI
Description: Withdrawal from cecum to sigmoid colon with Narrow Band Imaging (NBI, Evis Exera III, Olympus)
Study NCT02406547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WLE
Description: Withdrawal from cecum to sigmoid colon with High Definition White Light Endoscopy (WLE)
Study NCT03323918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ImPACT
Description: Teaching parents to train social communicative skills as outlined in arm description.
Study NCT03323918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: TAU can include targeting eating and sleeping problems, adaptive skills, or other goals.
Study NCT00649649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinapril Hydrochloride Tablets 40 mg
Description: 40mg, single dose fed
Study NCT00649649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Accupril® Tablets 40 mg
Description: 40mg, single dose fed
Study NCT03161392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Follow-up
Description: Group No ductal lesion will be submitted to follow-up with periodic breast ultrasonography/mammography every 6 months for 2 years.
Study NCT03161392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound-guided percutaneous biopsy
Description: Group Ductal lesion will be submitted to ultrasound-guided percutaneous biopsy and the specimen will be histologically analysed.
Study NCT01606995 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator
Study NCT01514734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide/timolol maleate fixed combination
Description: Commercially marketed topical ocular agent for the treatment of open-angle glaucoma (OAG) or ocular hypertension.
Study NCT01768676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: 100 mg
Study NCT01768676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01523249 — intervention group
Intervention type: DEVICE
Intervention: Lumbar 3D ultrasound scanning and palpation (Ultrasonix )
Description: Paramedian ultrasound scanning of L2-3 and L3-4 lumbar interspaces to visualize ligamentum flavum. Palpation of the same intervertebral spaces to identify spine midline and needle insertion point.
Study NCT04158999 — intervention group
Intervention type: DEVICE
Intervention: milk analyzer
Description: Human Milk Sample
Study NCT04158999 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mother's nutrition values
Description: evaluation of nutritional elements of maternal onset with Bebis Program
Study NCT00770978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftobiprole q12h
Description: Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
Study NCT00770978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftobiprole q8h
Description: Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
Study NCT01396291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)
Study NCT01396291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: asenapine-matched placebo, sublingual tablets, BID
Study NCT03488056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICCMS
Description: The patient's caries risk assessment, Diagnosis of caries lesion and activity assessment~-Intraoral risk assessment, Decide on a personalized care plan for patient and clinical interventions.~After asses all the factors and defining the patient's individual risk, the system presents a personalized treatment plan, indicating the appropriate home care instructions, clinical interventions and specific treatment for each caries lesion categories.~The treatment is divided into Non-Operative Care and Tooth-Preserving Operative Care (restorations with minimal intervention to preserve maximum dental structure).~The return intervals will be scheduled according to the risk: low risk (return of 1 year), moderate risk (6 months) and high risk (3 months)
Study NCT03488056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SESC standard care
Description: Standard care related to: Caries Diagnosis, operative and non-operative treatments, Indication of recall interval according to the dentist opinion
Study NCT02168335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OrasaltsTM
Description: OrasaltsTM mouthwash is composed of 119.5g of natural sea salt, Arnica montana 30C, Echinacea angustifolia 30C, Staphysagria 30C, Phosphorus 30C, Hepar sulphuris 30C, 0.27g cinnamon and 0.27g of liquorice
Study NCT02168335 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sea salt
Description: Unmedicated sea salt
Study NCT00939991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostst/Bevacizumab/Temozolomide
Description: Bevacizumab will be administered intravenously at the dose 10 mg/kg every other week. Temozolomide will be administered on a continuous daily dosing schedule at 50 mg/m2/day. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen. Bevacizumab doses may be given by the local oncologists under the direction of the Duke investigators.
Study NCT01838824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed of Processing Training
Description: SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself.
Study NCT02563769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally in capsules identical to CLAV and be filled with crystalline microcellulose
Study NCT00008138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: pre-surgery - target AUC=6, Day 1 IV, q 21 days X 3 cycles post-surgery - target AUC=5, Day 1 IP, q 28 days X 6 cycles
Study NCT00008138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: pre-surgery - 175 mg/m2 IV Day 1, q 21 days X 3 cycles post-surgery - 175 mg/m2 IV Day 1, q 28 days X 6 cycles AND 60 mg/m2 IP Day 8, q 28 days X 6 cycles
Study NCT00008138 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: debulking surgery
Description: exploratory laparotomy, interval cytoreduction (to \< 1 cm residual)
Study NCT04053543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10
Description: (10-nitro-9(E)-octadec-9enoic acid)
Study NCT00555828 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Precursor Cells (MPCs)
Description: 25 M allogeneic MPCs by transendocardial injection
Study NCT00555828 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard-of-care treatment with NOGA® mapping and staged injections.
Description: Standard-of-care treatment with NOGA® mapping and staged injections.
Study NCT00555828 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Precursor Cells (MPCs)
Description: 75 M allogeneic MPCs by transendocardial injection
Study NCT00555828 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Precursor Cells (MPCs)
Description: 150 M allogeneic MPCs by transendocardial injection
Study NCT03799718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NurOwn (MSC-NTF cells)
Description: Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
Study NCT02262039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valveless recirculating insufflation (VTI)
Description: 10 mmHg target pressure
Study NCT02262039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pressure
Description: 15 mmHg target pressure
Study NCT00528346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training using fMRI
Description: Participants will be scanned using fMRI while they employ the cognitive training strategies-allowing them to view their brain activity.
Study NCT00528346 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Some participants will see simulated data that does not come from their own brains.
Study NCT05270538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mask Zero Seam Virus Bac-Off Lupo® 98% Polyamide and 2% Elastane
Description: The 26 participants allocated as G2 had to perform the physical exercise using the Zero Sewing Virus Bac-Off Virus® 98% Polyamide and 2% Elastane, in order to totally seal the nose and mouth.
Study NCT03751995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Participants in the intervention group will have their choice of two commercially available mindfulness programs, HeadspaceTM and eMindful for 6 weeks.~The Headspace program provides progressive guided mindfulness meditation instruction via a website and mobile app to help users learn the skills of mindfulness for use in everyday life. Sessions last 3-20 minutes. Videos encourage the integration of mindfulness into daily life.~eMindful offers an online virtual classroom where participants can participate in synchronous, 1-hour mindfulness classes 1-2 times per week. The program is modeled after the mindfulness-based stress reduction (MBSR) program. eMindful also offers a cancer-specific meditation course that participants may choose to participate in.
Study NCT02292303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc-enriched yeast
Study NCT02292303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc references
Study NCT00258427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1.
Study NCT00258427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10\^9/L)
Study NCT01803516 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: This study will be offered to patients who, at the time of consultation are identified as having had adjuvant breast radiation treatment following surgical treatment for breast cancer and developed radiation-induced telangiectasias. The Skindex-16 and BREAST-Q questionnaires will be used to evaluate the quality of life of The study participants. For each instrument, for each evaluation time point, QOL scores will be summed and transformed into a scale from 0-100. Descriptive statistics will be used to describe the QOL of the study participants.
Study NCT01456078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-TATE
Description: 177Lu-DOTA-TATE given as intravenous infusion given during 3-5 treatments. Evaluation is performed after every single cycle. Further more, evaluation is made after last cycle, and delivered cumulative dose to kidneys should be 27 Gy.~Patients with stable disease or partial response, and without pronounced toxicity will continue treatment to a step 2, where additional 3-5 treatment cycles are given, with a cumulative dose to kidneys to 40 Gy.
Study NCT02864628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV
Description: MVA-mBN294B
Study NCT00258427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if \<4 years old)
Study NCT00258427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 10 mg/kg intravenously (IV) on Days -5 through -2.
Study NCT00258427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 35 mg/m\^2 intravenously (IV) on Days -5 through -2.
Study NCT00258427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1.
Study NCT02864628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris Buffered Saline
Study NCT01559519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: albumin 20% 1 g/Kg body weight for the first two days after TIPS followed by 0,5 g/Kg body weight at day 4 and then 0,5 g/Kg body weight once a week for three weeks.
Study NCT02551055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1117
Description: MLN1117 Tablets
Study NCT02551055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 Tablets
Study NCT02551055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib Tablets
Study NCT02551055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous infusion
Study NCT02551055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusion
Study NCT00430300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-432,097
Description: Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
Study NCT00430300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing 100% lactose administered BID using an atomizer device
Study NCT01597752 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control
Description: Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
Study NCT00775242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol and Progesterone
Description: Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.
Study NCT00775242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol and Progesterone
Description: Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period
Study NCT04021667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: İndividual and Group Breastfeeding Education:It was taken into consideration that mothers and fathers who do not have breastfeeding experience in the antenatal period feel better in terms of their perception of the education given, and education is provided with adult education principles.Breastfeeding training slides, cloth nipple model, dummy dolls were used during the training and lecture, demonstration and application and breastfeeding training were provided.At the end of the training, they were given time to ask questions and their feedback was received.Control Group:Routine procedures in the clinic were performed for the mother and father candidates.The data of the mother and father who came to the hospital for antenatal follow-up and control were collected in four stages.
Study NCT03245593 — intervention group
Intervention type: OTHER
Intervention: Shared-decision making process
Description: Completion of the Ottawa Personal Decision Guide to help guide care with the support of online and printed material describing the therapeutic options available
Study NCT03245593 — intervention group
Intervention type: OTHER
Intervention: standard care
Description: Care of patients according to standard practice of managing patients with bipolar disorder
Study NCT04361318 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine plus Nitazoxanide
Description: Both hydroxychloroquine \& nitazoxanide will be administered orally to participating patients
Study NCT02677974 — intervention group
Intervention type: DEVICE
Intervention: On-X Aortic Heart Valve replacement
Description: Aortic valve replacement with low dose warfarin
Study NCT01696136 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac ablation for Atrial Fibrillation
Description: Cardiac ablation for Atrial Fibrillation
Study NCT01082887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIL-Ad-INFg
Description: After verification of inclusion and non-inclusion criteria and after obtaining informed consent from the patients, a tumor sample will be taken for sterile production of TIL. Patients will receive intra-tumoral injections of Ad-INFg every 15 days from J-15 to M2, then every month from M3 to M11 or until disease progression. The Ad-INFg will be administered by intra-tumoral injection at a dose of 5x1010 vp (viral particles) per lesion. A maximum of 6 lesions will be treated simultaneously. They will also receive two infusion of TIL at M0 (Cycle 1) and M1 (Cycle 2) by intravenous infusion lasting 30 to 65 minutes followed by subcutaneous injections of IL2 from J1 to J5 and from J8 to J12 of each cycle.An evaluation of injected and not injected tumoral lesions including photographs will be realised at the pre-inclusion visit, J-15, M0 and every month until M12.
Study NCT02375217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: half dose
Study NCT00529048 — intervention group
Intervention type: OTHER
Intervention: Isoglycemic clamp
Description: I.v. glucose infusion initiating the glucose responds curves from the OGTT
Study NCT02375217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: full dose
Study NCT02375217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: IV = 50mcg/kg